Taken together, animal studies consistently show that eliminating AQP4 is beneficial in pure cytotoxic edema contexts but detrimental in vasogenic edema contexts (Table 1); the challenge moving forward is translating this knowledge into therapies that can modulate AQP4 at the right time and place to improve stroke outcomes. The gene discussed is AQP4; the disease is Stroke.